GE HealthCare
(Nasdaq: GEHC)
announced today that it launched its Invenia automated breast ultrasound (ABUS) premium offering.
The company’s latest 3D ultrasound offering includes advanced AI and other innovative features. It aims to drive faster, reproducible supplemental screening and streamline exam readings on patients with dense breasts.
GE HealthCare announced the new offering at the same time that it is expanding its AI partnership with Nvidia to include autonomous X-ray and ultrasound applications. (We have a full roundup of medtech AI news out of Nvidia’s GTC 2025 event this week.)
The Chicago-based medtech giant says approximately 71% of cancers occur in dense breasts. Studies across the U.S. and Europe show 40% of women (plus 70% of Asian women) have dense breast tissue, the company says. It notes growing evidence supporting ABUS as a tool for detecting cancer in these dense breasts with clearer, more detailed images. ABUS also can improve the sensitivity of detecting invasive cancer in dense breasts when added to mammography.
Designed to manage high patient volumes along the breast care pathway, Invenia ABUS also delivers high-quality images and boosts clinical confidence. New Verisound AI tools can help clinicians work smarter and more efficiently, the company says. The tools feature Scan Quality Assessment for immediate qualitative evaluation during the exam. Its new Fast Scan tool increases scan speed by up to 40% and cSound Imageformer capabilities automatically create focus at every pixel. This ensures consistent, high-resolution image quality and reproducibility.
Physicians can use Invenia ABUS Viewer with AI Assistant to quickly review and interpret patient exams. They can evaluate the exams either from their practice or remotely. The AI tools for review utilize intelligent algorithms to assist in detecting and characterizing breast lesions.
GE HealthCare plans to launch Invenia ABUS Premium, which has FDA premarket approval, in key countries throughout 2025.
“Women with dense breasts often face poorer outcomes due to malignancies detected at later, more advanced stages. Invenia ABUS Premium equipped with AI has the potential to optimize clinicians’ screening capabilities, enabling them to detect even small, early-stage cancers with a high degree of confidence in women with dense breasts,” said Karley Yoder, CEO of Comprehensive Care Ultrasound, GE HealthCare. “Invenia ABUS Premium is designed to help deliver the best possible outcomes for patients while also prioritizing the patient experience with features to improve scan speed and enhance comfort during an exam.”
